Catechol-O-methyltransferase: Effects of the val108met polymorphism on protein turnover in human cells

Biochimica et Biophysica Acta - General Subjects

Volumn 1780, Issue 1, 2008, Pages 27-33

  Doyle, Anne E ^a   Yager, James D ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Catechol O methyltransferase (COMT); COMT polymorphism; Human breast epithelial cell lines; Protein synthesis; Protein turnover

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHIONINE;

ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENOTYPE; HALF LIFE TIME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN STABILITY; PROTEIN SYNTHESIS; SINGLE NUCLEOTIDE POLYMORPHISM; TURNOVER TIME;

AMINO ACID SUBSTITUTION; BLOTTING, WESTERN; CATECHOL O-METHYLTRANSFERASE; CELL LINE; GENOTYPE; HUMANS; IMMUNOPRECIPITATION; METHIONINE; POLYMORPHISM, SINGLE NUCLEOTIDE; VALINE;

EID: 36749103757     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.10.002     Document Type: Article

References (37)

1. Lundstrom K., Tenhunen J., Tilgmann C., Karhunen T., Panula P., and Ulmanen I. Cloning, expression and structure of catechol-O-methyltransferase. Biochim. Biophys. Acta 1251 (1995) 1-10
2. Mannisto P.T., and Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51 (1999) 593-628
3. Zhu B.T. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab. 3 (2002) 321-349
4. Scanlon P.D., Raymond F.A., and Weinshilboum R.M. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science 203 (1979) 63-65
5. Boudikova B., Szumlanski C., Maidak B., and Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 48 (1990) 381-389
6. Lavigne J.A., Helzlsouer K.J., Huang H.Y., Strickland P.T., Bell D.A., Selmin O., Watson M.A., Hoffman S., Comstock G.W., and Yager J.D. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res. 57 (1997) 5493-5497
7. Thompson P.A., Shields P.G., Freudenheim J.L., Stone A., Vena J.E., Marshall J.R., Graham S., Laughlin R., Nemoto T., Kadlubar F.F., and Ambrosone C.B. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res. 58 (1998) 2107-2110
8. Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., and Shen C.Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59 (1999) 4870-4875
9. Matsui A., Ikeda T., Enomoto K., Nakashima H., Omae K., Watanabe M., Hibi T., and Kitajima M. Progression of human breast cancers to the metastatic state is linked to genotypes of catechol-O-methyltransferase. Cancer Lett. 150 (2000) 23-31
10. Mitrunen K., Jourenkova N., Kataja V., Eskelinen M., Kosma V.M., Benhamou S., Kang D., Vainio H., Uusitupa M., and Hirvonen A. Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer Epidemiol. Biomark. Prev. 10 (2001) 635-640
11. Yim D.S., Parkb S.K., Yoo K.Y., Yoon K.S., Chung H.H., Kang H.L., Ahn S.H., Noh D.Y., Choe K.J., Jang I.J., Shin S.G., Strickland P.T., Hirvonen A., and Kang D. Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics 11 (2001) 279-286
12. Mitrunen K., Kataja V., Eskelinen M., Kosma V.M., Kang D., Benhamou S., Vainio H., Uusitupa M., and Hirvonen A. Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk. Pharmacogenetics 12 (2002) 67-72
13. Tan W., Qi J., Xing D.Y., Miao X.P., Pan K.F., Zhang L., and Lin D.X. Relation between single nucleotide polymorphism in estrogen-metabolizing genes COMT, CYP17 and breast cancer risk among Chinese women. Zhonghua Zhong Liu Za Zhi 25 (2003) 453-456
14. Sazci A., Ergul E., Utkan N.Z., Canturk N.Z., and Kaya G. Catechol-O-methyltransferase Val 108/158 Met polymorphism in premenopausal breast cancer patients. Toxicology 204 (2004) 197-202
15. Bilder R.M., Volavka J., Lachman H.M., and Grace A.A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29 (2004) 1943-1961
16. Kunugi H., Nanko S., Ueki A., Otsuka E., Hattori M., Hoda F., Vallada H.P., Arranz M.J., and Collier D.A. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci. Lett. 221 (1997) 202-204
17. Goudreau J.L., Maraganore D.M., Farrer M.J., Lesnick T.G., Singleton A.B., Bower J.H., Hardy J.A., and Rocca W.A. Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease. Mov. Disord. 17 (2002) 1305-1311
18. Goodman J.E., Jensen L.T., He P., and Yager J.D. Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics 12 (2002) 517-528
19. Doyle A.E., Goodman J.E., Silber P.M., and Yager J.D. Catechol-O-methyltransferase low activity genotype (COMTLL) is associated with low levels of COMT protein in human hepatocytes. Cancer Lett. 214 (2004) 189-195
20. Shield A.J., Thomae B.A., Eckloff B.W., Wieben E.D., and Weinshilboum R.M. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry 9 (2004) 151-160
21. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., and Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75 (2004) 807-821
22. ATCC Cell Biology, Product Description, ATCC, www.atcc.org, 2006.
23. Bonifacino J.S. Chapter 7: protein labeling and immunoprecipitation, unit 7.1: metabolic labeling with amino acids. In: Yamada K.M. (Ed). Current Protocols in Cell Biology (2001), John Wiley & Sons, Inc., Indianapolis, IN
24. Davidson N.E., Gelmann E.P., Lippman M.E., and Dickson R.B. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol. Endocrinol. 1 (1987) 216-223
25. Journe F., Body J.J., Leclercq G., Nonclercq D., and Laurent G. Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma. Breast. Cancer Res. Treat. 86 (2004) 39-53
26. Spink D.C., Spink B.C., Cao J.Q., DePasquale J.A., Pentecost B.T., Fasco M.J., Li Y., and Sutter T.R. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19 (1998) 291-298
27. Lane M.A., Romagnoli L., Cruise B., and Cohn G.M. Spontaneous conversion to estrogen receptor expression by the human breast epithelial cell line, MCF-10A. Oncol. Rep. 6 (1999) 507-511
28. Liu S., and Lin Y.C. Transformation of MCF-10A human breast epithelial cells by zeranol and estradiol-17beta. Breast J. 10 (2004) 514-521
29. Lu M., Mira-y-Lopez R., Nakajo S., Nakaya K., and Jing Y. Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells. Oncogene 24 (2005) 4362-4369
30. Nackley A.G., Shabalina S.A., Tchivileva I.E., Satterfield K., Korchynskyi O., Makarov S.S., Maixner W., and Diatchenko L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314 (2006) 1930-1933
31. Zhou P. Determining protein half-lives. In: Mendenhall M.D. (Ed). Methods in Molecular Biology. Second Edition. Signal Transduction Protocols Vol. 284 (2004), Humana Press Inc., Totowa, NJ 67-78
32. Wickner S., Maurizi M.R., and Gottesman S. Posttranslational quality control: folding, refolding, and degrading proteins. Science 286 (1999) 1888-1893
33. Wang L., Yee V.C., and Weinshilboum R.M. Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system. Biochem. Biophys. Res. Commun. 325 (2004) 426-433
34. Johnston J.A., Ward C.L., and Kopito R.R. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143 (1998) 1883-1898
35. Wang L., Nguyen T.V., McLaughlin R.W., Sikkink L.A., Ramirez-Alvarado M., and Weinshilboum R.M. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9394-9399
36. Siegel D., Anwar A., Winski S.L., Kepa J.K., Zolman K.L., and Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol. Pharmacol. 59 (2001) 263-268
37. Ohnishi A., and Emi Y. Rapid proteasomal degradation of translocation-deficient UDP-glucuronosyltransferase 1A1 proteins in patients with Crigler-Najjar type II. Biochem. Biophys. Res. Commun. 310 (2003) 735-741